Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BPTES |
Synonyms | |
Therapy Description |
BPTES is a small molecule that inhibits glutaminase, which results in decreased conversion of glutamine to glutamate, and potentially leads to decreased tumor cell growth (PMID: 21045145, PMID: 25915584, PMID: 32450839). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BPTES | bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide | Glutaminase Inhibitor 3 | BPTES is a small molecule that inhibits glutaminase, which results in decreased conversion of glutamine to glutamate, and potentially leads to decreased tumor cell growth (PMID: 21045145, PMID: 25915584, PMID: 32450839). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
IDH1 R132H | high grade glioma | sensitive | BPTES | Preclinical - Cell culture | Actionable | In a preclinical study, a glioma cell line expressing IDH1 R132H demonstrated increased sensitivity to growth inhibition by BPTES compared to a cell line expressing wild-type IDH1 in culture (PMID: 21045145). | 21045145 |
VHL loss | renal cell carcinoma | sensitive | BPTES | Preclinical - Cell culture | Actionable | In a preclinical study, VHL-deficient renal cell carcinoma cells demonstrated growth inhibition and suppression of DNA synthesis in culture when treated with BPTES (PMID: 28346230). | 28346230 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|